WO2003101425A3 - Therapeutic agent-containing polymeric nanoarticles - Google Patents

Therapeutic agent-containing polymeric nanoarticles Download PDF

Info

Publication number
WO2003101425A3
WO2003101425A3 PCT/US2003/017536 US0317536W WO03101425A3 WO 2003101425 A3 WO2003101425 A3 WO 2003101425A3 US 0317536 W US0317536 W US 0317536W WO 03101425 A3 WO03101425 A3 WO 03101425A3
Authority
WO
WIPO (PCT)
Prior art keywords
nanoarticles
therapeutic agent
containing polymeric
drug
covalently attached
Prior art date
Application number
PCT/US2003/017536
Other languages
French (fr)
Other versions
WO2003101425A2 (en
WO2003101425A8 (en
Inventor
Stephen E Barry
Andrew A Goodwin
Rachel Decor
Original Assignee
Alnis Biosciences Inc
Stephen E Barry
Andrew A Goodwin
Rachel Decor
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alnis Biosciences Inc, Stephen E Barry, Andrew A Goodwin, Rachel Decor filed Critical Alnis Biosciences Inc
Priority to AU2003273272A priority Critical patent/AU2003273272A1/en
Priority to EP03741863A priority patent/EP1531868A2/en
Priority to JP2004508783A priority patent/JP2005535604A/en
Priority to CA002487720A priority patent/CA2487720A1/en
Publication of WO2003101425A2 publication Critical patent/WO2003101425A2/en
Priority to US10/995,880 priority patent/US20050129769A1/en
Publication of WO2003101425A3 publication Critical patent/WO2003101425A3/en
Publication of WO2003101425A8 publication Critical patent/WO2003101425A8/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/57—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C323/58—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton
    • C07C323/59—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton with acylated amino groups bound to the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A61K47/6933—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained by reactions only involving carbon to carbon, e.g. poly(meth)acrylate, polystyrene, polyvinylpyrrolidone or polyvinylalcohol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A61K47/6935—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A61K47/6939—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being a polysaccharide, e.g. starch, chitosan, chitin, cellulose or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface

Abstract

Hydrophilic polymeric articles comprising a polymeric scaffold covalently attached to one or more therapeutic agents, such as drug or drug-conjugate molecules. The articles may further covalently attached comprise recognition elements (REs) that bind to biomolecular structures expressed on certain cells or in certain tissues, to facilitate targeting and/or delivery.
PCT/US2003/017536 2002-06-03 2003-06-03 Therapeutic agent-containing polymeric nanoarticles WO2003101425A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU2003273272A AU2003273272A1 (en) 2002-06-03 2003-06-03 Therapeutic agent-containing polymeric nanoarticles
EP03741863A EP1531868A2 (en) 2002-06-03 2003-06-03 Therapeutic agent-containing polymeric nanoarticles
JP2004508783A JP2005535604A (en) 2002-06-03 2003-06-03 Polymer nano-articles containing therapeutic agents
CA002487720A CA2487720A1 (en) 2002-06-03 2003-06-03 Therapeutic agent-containing polymeric nanoarticles
US10/995,880 US20050129769A1 (en) 2002-06-03 2004-11-22 Polymeric articles for carrying therapeutic agents

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US38553702P 2002-06-03 2002-06-03
US60/385,537 2002-06-03
US46316203P 2003-04-16 2003-04-16
US60/463,162 2003-04-16

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/995,880 Continuation-In-Part US20050129769A1 (en) 2002-06-03 2004-11-22 Polymeric articles for carrying therapeutic agents

Publications (3)

Publication Number Publication Date
WO2003101425A2 WO2003101425A2 (en) 2003-12-11
WO2003101425A3 true WO2003101425A3 (en) 2005-03-17
WO2003101425A8 WO2003101425A8 (en) 2005-04-28

Family

ID=29715373

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/017536 WO2003101425A2 (en) 2002-06-03 2003-06-03 Therapeutic agent-containing polymeric nanoarticles

Country Status (5)

Country Link
EP (1) EP1531868A2 (en)
JP (1) JP2005535604A (en)
AU (1) AU2003273272A1 (en)
CA (1) CA2487720A1 (en)
WO (1) WO2003101425A2 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005027873A2 (en) * 2003-06-20 2005-03-31 Alnis Biosciences, Inc. Therapeutic aminoglycoside-containing hydrogel nanoparticles
WO2005065724A1 (en) * 2003-12-30 2005-07-21 Alnis Biosciences, Inc. Formulations of paramagnetic ion complexes
WO2005070471A2 (en) * 2004-01-20 2005-08-04 Alnis Biosciences, Inc. Articles comprising magnetic material and bioactive agents
US7968085B2 (en) 2004-07-05 2011-06-28 Ascendis Pharma A/S Hydrogel formulations
EP2594291A1 (en) * 2004-07-05 2013-05-22 Ascendis Pharma GmbH Hydrogel
JP5319278B2 (en) * 2005-05-27 2013-10-16 ロイヤー バイオメディカル， インク． Bioresorbable polymer matrix and methods of making and using the same
EP2399610A3 (en) * 2007-09-24 2012-09-05 Bar-Ilan University Polymer nanoparticles coated by magnetic metal oxide and uses thereof
WO2010042638A2 (en) 2008-10-07 2010-04-15 Young Bok Lee Hpma - docetaxel or gemcitabine conjugates and uses therefore
DK2379114T3 (en) 2008-12-16 2014-09-29 Univ Santiago Compostela Conjugates comprising nanoparticles coated with platinum containing compounds
WO2011012718A1 (en) 2009-07-31 2011-02-03 Ascendis Pharma As Prodrugs comprising an insulin linker conjugate
ES2636741T3 (en) 2009-07-31 2017-10-09 Sanofi-Aventis Deutschland Gmbh Long-acting insulin composition
KR20150058554A (en) 2009-10-13 2015-05-28 렉산 파마슈티컬스, 인코포레이티드 Polymeric systems for the delivery of anticancer agents
CN101864071B (en) * 2010-05-21 2011-12-21 北京中海康医药科技发展有限公司 Polyethylene glycol-distearoyl phosphatidyl ethanolamine derivant and preparation method thereof
EP2438930A1 (en) 2010-09-17 2012-04-11 Sanofi-Aventis Deutschland GmbH Prodrugs comprising an exendin linker conjugate
US10285943B2 (en) 2010-12-02 2019-05-14 Greenmark Biomedical Inc. Aptamer bioconjugate drug delivery device
JP6258202B2 (en) * 2011-09-08 2018-01-10 ウェスタン ユニバーシティ オブ ヘルス サイエンス Targeted liposomes in cancer therapy
PL221351B1 (en) * 2012-03-14 2016-03-31 Politechnika Warszawska Method for obtaining polysaccharide nanoparticles
WO2017201407A1 (en) * 2016-05-20 2017-11-23 Massachusetts Institute Of Technology Hydrogel particle of cystamine cross-linked dextran aldehyde containing imine conjugated doxorubicin and rgd peptide for chemotherapy
JP2021519310A (en) 2018-03-28 2021-08-10 グリーンマーク バイオメディカル インコーポレイテッドＧｒｅｅｎＭａｒｋ Ｂｉｏｍｅｄｉｃａｌ， Ｉｎｃ． Phosphate cross-linked starch nanoparticles and dental treatment

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5415864A (en) * 1990-04-18 1995-05-16 University Of Utah Research Foundation Colonic-targeted oral drug-dosage forms based on crosslinked hydrogels containing azobonds and exhibiting PH-dependent swelling
US5562099A (en) * 1990-10-05 1996-10-08 Massachusetts Institute Of Technology Polymeric microparticles containing agents for imaging
US5702727A (en) * 1993-02-22 1997-12-30 Alza Corporation Compositions and methods for the oral delivery of active agents
EP0838224A2 (en) * 1996-10-02 1998-04-29 Kuraray Co., Ltd. Polymer-drug conjugates with an enzyme cleavable linker
WO2000009088A1 (en) * 1998-08-14 2000-02-24 Incept Llc Composite hydrogel drug delivery systems
WO2001015738A2 (en) * 1999-09-02 2001-03-08 Rice University Nitric oxide-producing hydrogel materials
WO2001078786A2 (en) * 2000-04-14 2001-10-25 Alnis Biosciences, Inc. High affinity peptide-containing nanoparticles

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5415864A (en) * 1990-04-18 1995-05-16 University Of Utah Research Foundation Colonic-targeted oral drug-dosage forms based on crosslinked hydrogels containing azobonds and exhibiting PH-dependent swelling
US5562099A (en) * 1990-10-05 1996-10-08 Massachusetts Institute Of Technology Polymeric microparticles containing agents for imaging
US5702727A (en) * 1993-02-22 1997-12-30 Alza Corporation Compositions and methods for the oral delivery of active agents
EP0838224A2 (en) * 1996-10-02 1998-04-29 Kuraray Co., Ltd. Polymer-drug conjugates with an enzyme cleavable linker
WO2000009088A1 (en) * 1998-08-14 2000-02-24 Incept Llc Composite hydrogel drug delivery systems
WO2001015738A2 (en) * 1999-09-02 2001-03-08 Rice University Nitric oxide-producing hydrogel materials
WO2001078786A2 (en) * 2000-04-14 2001-10-25 Alnis Biosciences, Inc. High affinity peptide-containing nanoparticles

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BOUHADIR K H ET AL: "Hydrogels for combination delivery of antineoplastic agents", BIOMATERIALS, ELSEVIER SCIENCE PUBLISHERS BV., BARKING, GB, vol. 22, no. 19, 1 October 2001 (2001-10-01), pages 2625 - 2633, XP004296082, ISSN: 0142-9612 *
BOUHADIR KAMAL H ET AL: "Sustained and controlled release of daunomycin from cross-linked poly(aldehyde guluronate) hydrogels", JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 89, no. 7, July 2000 (2000-07-01), pages 910 - 919, XP002261385, ISSN: 0022-3549 *
CAIOLFA V R ET AL: "Polymer-bound camptothecin: initial biodistribution and antitumour activity studies", JOURNAL OF CONTROLLED RELEASE, ELSEVIER SCIENCE PUBLISHERS B.V., AMSTERDAM, NL, vol. 65, no. 1-2, March 2000 (2000-03-01), pages 105 - 119, XP004190316, ISSN: 0168-3659 *
DENNY WILLIAM A ET AL: "The design of selectively-activated anti-cancer prodrugs for use in antibody-directed and gene-directed enzyme-prodrug therapies", JOURNAL OF PHARMACY AND PHARMACOLOGY, vol. 50, no. 4, April 1998 (1998-04-01), pages 387 - 394, XP009020713, ISSN: 0022-3573 *
GOLDBERG EUGENE P: "POLYMERIC AFFINITY DRUGS FOR CARDIOVASCULAR, CANCER AND UROLITHIASIS THERAPY", 173RD;NEW ORLEANS, LA, USA MAR 20-25 1977, vol. 18, no. 1, March 1977 (1977-03-01), Am Chem Soc Div Polym Chem Prepr Mar 1977, pages 575 - 580, XP009020428 *
LLOYD JOHN B ET AL: "SOLUBLE SYNTHETIC POLYMERS AS TARGETABLE AGENTS FOR INTRACELLULAR DRUG RELEASE", PAP PRESENTED AT THE POLYM AS DRUG RELEASE AGENTS SYMP;LONDON, ENGL MAR 23 1983, vol. 15, no. 4, 23 March 1983 (1983-03-23), Br Polym J Dec 1983, pages 158 - 159, XP009020432 *
VERVOORT LIESBETH ET AL: "Inulin hydrogels as carriers for colonic drug targeting: I. Synthesis and characterization of methacrylated inulin and hydrogel formation", PHARMACEUTICAL RESEARCH (NEW YORK), vol. 14, no. 12, December 1997 (1997-12-01), pages 1730 - 1737, XP009020453, ISSN: 0724-8741 *

Also Published As

Publication number Publication date
AU2003273272A1 (en) 2003-12-19
WO2003101425A2 (en) 2003-12-11
CA2487720A1 (en) 2003-12-11
JP2005535604A (en) 2005-11-24
AU2003273272A8 (en) 2003-12-19
WO2003101425A8 (en) 2005-04-28
EP1531868A2 (en) 2005-05-25

Similar Documents

Publication Publication Date Title
WO2003101425A8 (en) Therapeutic agent-containing polymeric nanoarticles
WO2003011226A3 (en) Products and drug delivery vehicles
WO2007041584A3 (en) Implantable sensors, implantable pumps, and anti-scarring drug combinations
WO2005044224A3 (en) Drug delivery system based on polymer nanoshells
WO2005099667A3 (en) Drug delivery compositions
WO2007076371A3 (en) Hydrophobic core carrier compositions for delivery of therapeutic agents, methods of making and using the same
AU2002339993A1 (en) P-amidobenzylethers in drug delivery agents
EP1201230A3 (en) Solution-based transdermal drug delivery system comprising a vasodilator
WO2005025499A3 (en) Hydrophobic drug compositions containing reconstitution enhancer
WO2004000389A3 (en) Rapidly dissolving micro-perforator for drug delivery and other applications
AU2003267581A1 (en) Drug delivery
AU2003217531A1 (en) Ocular drug delivery systems and use thereof
WO2006039558A3 (en) Ocular agent delivery systems
WO2003049772A3 (en) Guanidinium transport reagents and conjugates
WO2007148230A3 (en) Grafted polymers and uses thereof
EP1941839A3 (en) Medical devices with cutting element
IL175601A0 (en) Excipients in drug delivery vehicles
EP1691826A4 (en) Excipients in drug delivery vehicles
WO2005027794A3 (en) Medical devices
WO2006138099A3 (en) Bone morphogenetic protein formulations
WO2006121522A3 (en) Implantable sensors and pumps, anti-scarring agents, and therapeutic compositions
WO2004056852A3 (en) Cyanovirin variant-polymer conjugates
WO2003028696A8 (en) Compositions for delivery of drug combinations
AUPQ879500A0 (en) Hyaluronan as cytotoxic agent, drug presensitizer and chemo-sensitizer in the treatment of disease
WO2003074033A8 (en) Sustained/controlled release solid formulation as a novel drug delivery system with reduced risk of dose dumping

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 10995880

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2487720

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2004508783

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2003741863

Country of ref document: EP

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 50/2003 UNDER (71) THE NAME/ADDRESS SHOULD READ "ALNIS BIOSCIENCES, INC."

WWP Wipo information: published in national office

Ref document number: 2003741863

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2003741863

Country of ref document: EP